The injection pen of Eli Lilly and Company’s weight loss drug Zepbound is on display in New York City, the United States, on December 11, 2023.
Brendan McDermid | Reuters
most doses Eli Lilly and CompanyPopular weight loss drug Zepbound and diabetes drug Mounjaro will experience supply shortages in the second quarter of this year as demand surges, according to a company. renew Wednesday’s U.S. Food and Drug Administration drug shortage database.
All doses of Zepbound and Mounjaro are in shortage except for the 2.5 mg version. A Previous updates says some doses of both drugs are in limited supply through April.
A new update shows that insatiable demand for a popular class of weight loss and diabetes drugs continues to be in short supply despite Eli Lilly and its main rivals. Novo Nordisk Efforts are being made to increase the production of these treatments.
Many patients are struggling to find injectable treatments, and the need to help them lose weight has surged over time. These treatments are sometimes called incretin drugs, which mimic gut hormones to suppress appetite and regulate blood sugar.
Eli Lilly did not immediately respond Wednesday to a request for comment on the FDA update.
Eli Lilly said in February that it had achieved its goal of doubling its production capacity for such incretin drugs by the end of 2023. Growth occurs in the second half of 2023.
By that time this year, the company expects to increase production of salable doses of its incretin drug by at least 1.5 times compared with the second half of 2023.
Eli Lilly also said that a new plant in Concord, North Carolina, could begin producing incretin drugs as soon as the end of this year, with products to be shipped in 2025. .
Novo Nordisk announced a similar effort. Some doses of Novo Nordisk’s weight-loss drug Wegovy and diabetes drug Ozempic are also in short supply, according to the FDA website.
About The Author
